Juhee Kim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Juhee Kim has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Chang Ohk Sung
Department of Pathology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
1 shared publication Hee Cheol Kim
Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
1 shared publicationInsuk Sohn
Arontier Inc., Gangnam-daero, Seoul, Republic of Korea
1 shared publicationJeong-Ryeol Gong
Department of Bio and Brain Engineering, Korea Advanced Institute of Science and Technology, Daejeon, Republic of Korea
1 shared publication- Keun-Woo Lee
Department of Health Science and Technology, Samsung Advanced Institute for Health Science and Technology, Sungkyunkwan University, Seoul, Republic of Korea
1 shared publication - Kwang-Hyun Cho
Department of Bio and Brain Engineering, Korea Advanced Institute of Science and Technology
1 shared publication
Latest Publications
- Open Access
- 19 May 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-23
PRRX1 is a master transcription factor of stromal fibroblasts for myofibroblastic lineage progression
Although stromal fibroblasts play a critical role in cancer progression, their identities remain unclear as they exhibit high heterogeneity and plasticity. Here, a master transcription factor (mTF) constructing core-regulatory circuitry, PRRX1, which determines the fibroblast lineage with a myofibroblastic phenotype, is identified for the fibroblast subgroup. PRRX1 orchestrates the functional drift of fibroblasts into myofibroblastic phenotype via TGF-β signaling by remodeling a super-enhancer landscape. Such reprogrammed fibroblasts have myofibroblastic functions resulting in markedly enhanced tumorigenicity and aggressiveness of cancer. PRRX1 expression in cancer-associated fibroblast (CAF) has an unfavorable prognosis in multiple cancer types. Fibroblast-specific PRRX1 depletion induces long-term and sustained complete remission of chemotherapy-resistant cancer in genetically engineered mice models. This study reveals CAF subpopulations based on super-enhancer profiles including PRRX1. Therefore, mTFs, including PRRX1, provide another opportunity for establishing a hierarchical classification system of fibroblasts and cancer treatment by targeting fibroblasts.
- 19 May 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-23
Open AccessPRRX1 is a master transcription factor of stromal fibroblasts for myofibroblastic lineage progression
Although stromal fibroblasts play a critical role in cancer progression, their identities remain unclear as they exhibit high heterogeneity and plasticity. Here, a master transcription factor (mTF) constructing core-regulatory circuitry, PRRX1, which determines the fibroblast lineage with a myofibroblastic phenotype, is identified for the fibroblast subgroup. PRRX1 orchestrates the functional drift of fibroblasts into myofibroblastic phenotype via TGF-β signaling by remodeling a super-enhancer landscape. Such reprogrammed fibroblasts have myofibroblastic functions resulting in markedly enhanced tumorigenicity and aggressiveness of cancer. PRRX1 expression in cancer-associated fibroblast (CAF) has an unfavorable prognosis in multiple cancer types. Fibroblast-specific PRRX1 depletion induces long-term and sustained complete remission of chemotherapy-resistant cancer in genetically engineered mice models. This study reveals CAF subpopulations based on super-enhancer profiles including PRRX1. Therefore, mTFs, including PRRX1, provide another opportunity for establishing a hierarchical classification system of fibroblasts and cancer treatment by targeting fibroblasts.